PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 3555733
• 负责人: DONALD J FERNBACH
• 金额: $ 21.47万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 1991-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3555733
• 关键词: 6 thiopurine; Hodgkin's disease; acute leukemia; astrocytoma; central nervous system neoplasms; child (0-11); cis platinum compound; combination cancer therapy; combination chemotherapy; cooperative study; cryopreservation; cyclophosphamide; daunorubicin; human T cell leukemia; human subject; human therapy evaluation; immunodeficiency; lymphocytic leukemia; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neuroblastoma; pediatric neoplasm /cancer; prednisone; vincristine

The Department of Pediatrics, Baylor College of Medicine, has participated in cooperative cancer study group activities (Southwest Cancer Chemotherapy Study Group, Southwest Oncology Group, Pediatric Oncology Group) for 26 years. The basic purpose of the group has been to search for better methods of treatment by which to cure or control cancer in children. As a result of these activities, more than 50% of the children with cancer can now be expected to survive their disease. In the evolutionary development of these groups, increasing emphasis has been placed upon coordinating multidisciplinary care and on expanding fundamental knowledge of cancer biology and pathophysiology. Essential information on the natural history of specific disease entities has provided important knowledge of prognostic factors that are critical elements of modern experimental design. Biostatistical involvement has become as essential part of the integrated programs that now include equal participation by the medical oncology, surgery, pathology, and radiotherapy disciplines. This project will continue this highly successful process.

贝勒医学院儿科学系已参加 在合作癌症研究小组活动中（西南癌症化疗 研究小组，西南肿瘤学组，儿科肿瘤学小组）26 年。 小组的基本目的是更好地寻找 治疗儿童治疗或控制癌症的治疗方法。 作为 这些活动的结果，超过50％的癌症儿童可以 现在可以预期能够生存他们的疾病。 在进化发展中 在这些群体中，越来越重的重点已放在协调上 多学科护理以及扩大癌症的基本知识 生物学和病理生理学。 关于自然历史的基本信息 特定疾病实体提供了预后的重要知识 是现代实验设计的关键要素的因素。 生物统计参与已成为综合的重要组成部分 现在包括医学肿瘤学平等参与的计划， 手术，病理和放射疗法学科。 这个项目将 继续这个非常成功的过程。